Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This is an open phase II multicentre study evaluating the efficacy and safety of the non
pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line
treatment of patients with metastatic HER2/neu negative breast cancer.